Brief: Sanofi's rare lung disease drug outperforms standard care in trial
18/05/2026 20:30
May 18 (Reuters) - Sanofi SA SASY.PA: SANOFI: EFDORALPRIN ALFA DOSED EVERY THREE WEEKS ACHIEVED MEAN INCREASES IN FAAT TROUGH LEVELS 3X GREATER THAN PLASMA-DERIVED PROTEIN DOSED WEEKLY SANOFI: ELEVAATE PHASE 2 STUDY SHOWS EFDORALPRIN ALFA NORMALIZED MAINTAINED FUNCTIONAL AAT LEVELS IN PEOPLE WITH ALPHA-1 ANTITRYPSIN DEFICIENCY SANOFI: ALL KEY SECONDARY ENDPOINTS IN ELEVAATE PHASE 2 STUDY WERE ALSO MET SANOFI: EFDORALPRIN ALFA WAS WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLASMA-DERIVED PROTEIN Further company coverage: SASY.PA
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes